Last reviewed · How we verify
FZ-AD005
At a glance
| Generic name | FZ-AD005 |
|---|---|
| Sponsor | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) (PHASE1)
- A Study of FZ-AD005 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FZ-AD005 CI brief — competitive landscape report
- FZ-AD005 updates RSS · CI watch RSS
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. portfolio CI